Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de segurança e tolerabilidade do ST-503 para dor refratária associada à neuropatia de fibra pequena

30 de outubro de 2026 atualizado por: Sangamo Therapeutics

Um estudo de escalada de dose duplo-cego, randomizada e controlada por farsa e farsa para determinar a segurança e a tolerabilidade da terapia genética intratecal de ST-503 de dose única para dor refratária devido à neuropatia de fibra pequena idiopática (ISFN)

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

Visão geral do estudo

Status

Suspenso

Descrição detalhada

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.

Tipo de estudo

Intervencional

Inscrição (Estimado)

27

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85260
        • HonorHealth
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University of Arkansas for Medical Sciences
    • California
      • La Jolla, California, Estados Unidos, 92093
        • The University of California, San Diego
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21218
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03766
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York, New York, Estados Unidos, 10027
        • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • University of North Carolina Medical Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37235
        • Vanderbilt University
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • University of Utah
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23284
        • Virginia Commonwealth University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
  2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
  3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit

Exclusion Criteria

  1. Drug- and alcohol-related:

    1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
    2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
    3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
    4. Use of cannabinoids is not permitted.
  2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies

  3. Procedure-related:

    1. Contraindications to LP, general anesthesia or sedation
    2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
  4. Infectious disease-related:

    1. Active viral infection or bacterial
    2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
  5. Hepatic disease- and hepatotoxic medication-related:

    1. Presence of clinically relevant liver disease
    2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
    3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
    4. Hepatotoxic supplement use during the study period
  6. Cancer-related:

    a. History of cancer, including B-cell cancers, within 5 years of Screening

    i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months

    b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation

  7. Previously received gene or cellular therapy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Falso: Estudo controlado por simulação

Sham Procedure

Experimental: Agente de investigação

Genomic Medicine

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence and severity of treatment emergent adverse events (TEAEs)
Prazo: 12 weeks

To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.

12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of subjects with pain intensity reduction from baseline at Week 12
Prazo: 12 weeks
  • 30% in the weekly average of daily pain intensity measurements performed using the PI-NRS

  • 50% in the weekly average of daily pain intensity measurements performed using the PI-NRS

    • Dose of rescue medication use
    • Frequency of rescue medication use
12 weeks
Percentage of subjects at Week 12
Prazo: 12 weeks
  • Categorized as improved on the patient global impression of change (PGIC) assessment
  • With a ≥ 1-point improvement in suicidal ideation in Columbia Suicide Severity Rating Scale (C-SSRS) responses
12 weeks
Columbia Suicide Severity Rating Scale (CSSRS) Rating
Prazo: 12 weeks

With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses

12 weeks
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
Prazo: 12 Weeks

Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary.

12 Weeks
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
Prazo: 12 Weeks

This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week.

12 Weeks
Daily Sleep Interference Score (DSIS)
Prazo: 12 Weeks

DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe).

12 Weeks
Hospital Anxiety and Depression Scale (HADS)
Prazo: 12 Weeks

HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms.

12 Weeks
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
Prazo: 12 Weeks

The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms.

12 Weeks
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
Prazo: 12 Weeks

The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability.

12 Weeks
36-Item Short Form Health Survey (SF-36) domains and summary scores
Prazo: 12 Weeks

This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life.

12 Weeks
Pain Catastrophizing Questionnaire (PCS)
Prazo: 12 Weeks

PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present.

12 Weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Medical Monitor, Sangamo Therapeutics Inc.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de dezembro de 2025

Conclusão Primária (Estimado)

1 de julho de 2027

Conclusão do estudo (Estimado)

1 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

30 de abril de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de maio de 2025

Primeira postagem (Real)

20 de maio de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever